CAT announces Phase II CAT-152 data

Cambridge Antibody (LSE:CAT; CATG) said its CAT-152 lerdelimumab met the primary end point of safety and tolerability in a Phase II study, but did not significantly reduce intraocular pressure (IOP) compared to placebo, the study's secondary endpoint. The product is an anti-TGFbeta(2) monoclonal antibody. ...